Pretreatment Serum Albumin Level is an Independent Prognostic Factor in Patients with Stage IIIB Non-Small Cell Lung Cancer: A Study of the Turkish Descriptive Oncological Researches Group.

Ozgur Tanriverdi,Gamze Goksel,Nilufer Avci,Nezih Meydan,Suna Cokmert,Serkan Menekse,Kezban Nur Pilanci,Sabri Barutca,Muharrem Kocar,Esin Oktay,Serdar Kalemci,Cenk Ahmet Sen,Tulay Akman,Cetin Ordu

doi:10.7314/apjcp.2015.16.14.5971

Ozgur Tanriverdi, Gamze Goksel + Show 12 more

Open Access

https://doi.org/10.7314/apjcp.2015.16.14.5971

Copy DOI

Abstract

Several prognostic factors have been studied in NSCLC, although it is unknown which is most useful. In this study, we aimed to investigate whether pre-treatment serum albumin level has prognostic value in patients with Stage IIIB NSCLC. This cross-sectional study included a total of 204 patients with Stage IIIB NSCLC who met the inclusion criteria. Pre-treatment serum albumin levels and demographic, clinical, and histological characteristics, as well as laboratory variables were recorded. A cut-off value was defined for serum albumin level and the patients were stratified into four groups on thios basis. The majority of the patients was males and smokers, with a history of weight loss, and squamous histological type of lung cancer. The mean serum albumin level was 3.2±1.7 g/dL (range, 2.11-4.36 g/dL). A cut-off value 3.11 g/dL was set and among the patients with a lower level, 68% had adenocarcinoma and 82% were smokers. The patients with low serum albumin levels had a lower response rate to e first-line chemotherapy with a shorter progression-free survival and overall survival. Multivariate analysis showed that low serum albumin level was an independent poor prognostic factor for NSCLC. This study results suggest that low serum albumin level is an independent poor prognostic factor in patients with Stage IIIB NSCLC, associated with reduction in the response rate to first-line therapy and survival rates.

Highlights

Lung cancer, which is one of the most common cancers in men and women, is one of the leading causes of cancerrelated deaths worldwide (Siegel et al, 2014)
We aimed to investigate whether pre-treatment serum albumin level has prognostic value in patients with Stage IIIB Non-small cell lung cancer (NSCLC)
Several prognostic factors have been studied in NSCLC including stage, performance status, sex, age, and histological type, which are commonly used in the clinical practice (Berghmans et al, 2011)

Summary

Introduction

Lung cancer, which is one of the most common cancers in men and women, is one of the leading causes of cancerrelated deaths worldwide (Siegel et al, 2014). Some authors have demonstrated that certain biological characteristics including lactate dehydrogenase, hypercalcemia, alkaline phosphatase, leukocytosis, and neutrophil counts, as well as patient characteristics including weight loss, smoking habits, comorbidities, and ethnicity and tumor features including histological degree, number of metastatic sites, vascular or local invasion, malign pleural effusion, and localization of the primary tumor may be potential prognostic factors in NSCLC.3-5 It is still unknown, which one is more useful and independent factor in the prognosis of the disease (Berghmans et al, 2011; Tanriverdi et al, 2014). Conclusions: This study results suggest that low serum albumin level is an independent poor prognostic factor in patients with Stage IIIB NSCLC, associated with reduction in the response rate to first-line therapy and survival rates

Objectives

Methods

Findings

Conclusion